MEDS serves as the ticker for DataMEDS AI, Inc., a healthcare technology company working to link the digital, pharmaceutical, and clinical elements of care within a single organization. I follow names like this because they sit at the crossroads of timely themes such as artificial intelligence, telemedicine, pharmacy innovation, and precision medicine, all within a relatively small, early-stage public entity.
DataMEDS AI positions itself as a health IT business centered on vertically integrating technology, pharmacy, pharmaceutical-adjacent activities, and telemedicine units. The aim is to create a smoother healthcare experience for patients by pairing software platforms with actual pharmacy operations.
Headquartered in Tampa, Florida, the shares trade on the Nasdaq Capital Market, a venue often linked to smaller and earlier-stage issuers. The company was incorporated in 2022 and operated as Wellgistics Health, Inc. until the July 2026 name change to DataMEDS AI, Inc.
Its technology lineup focuses on several key platforms. EinsteinRx functions as an AI-powered pharmacy-dispensing tool, while PharmacyChain provides a blockchain-enabled smart-contracts system for pharmaceutical transactions. Additional components include the Patient Rx Adherence Tool to help with medication compliance and HubRx AI as part of broader hub and clinical-services technology.
Alongside these digital tools, the company maintains a pharmacy distribution operation and delivers clinical concierge services. A subsidiary is also developing precision-medicine oncology solutions intended to assist physicians and patients with complex cancer-care decisions.
Operating as a holding company, DataMEDS AI oversees subsidiaries that handle wholesale and retail pharmaceutical products alongside technology and clinical services. The model mixes recurring software revenue with transaction-based pharmacy distribution, creating multiple potential income streams across the healthcare supply chain. This combination of technology and physical operations defines its vertical-integration approach.
The company competes in a wide, fragmented healthcare-technology space that features established pharmacy distributors, telehealth providers, and health IT software firms. As a small-cap name, its position remains early-stage, with differentiation coming from the blend of AI and blockchain tools paired with hands-on pharmacy services rather than a narrow product focus.
Investor interest in MEDS largely reflects exposure to ongoing healthcare technology themes. The use of AI in pharmacy dispensing and clinical workflows matches industry efforts to boost efficiency and lower costs. Its precision-medicine and oncology work through a subsidiary aligns with expanding personalized cancer care.
The vertical-integration strategy, which pairs proprietary software with pharmacy distribution and clinical services, also stands out because it lets the business capture value at several points along the pharmaceutical journey. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. For those focused on small-cap and emerging health IT names, DataMEDS AI offers a single publicly traded vehicle for these themes.
Like many small, early-stage healthcare companies, DataMEDS AI faces notable risks. Its financial profile shows continued investment in growth rather than consistent profitability, with net losses reported in recent periods. Limited size can constrain resources when competing against larger, better-funded players in pharmacy distribution and health IT.
Regulatory exposure is another factor, given that pharmaceutical distribution, telehealth, and clinical services fall under extensive U.S. healthcare rules. Reliance on newer technologies such as AI and blockchain means adoption and proven value at scale are still developing. Multiple name and strategic shifts in a short time add execution and brand challenges, and shares on the Nasdaq Capital Market can exhibit meaningful price swings.
DataMEDS AI remains an early-stage health IT company aiming to stand apart through the combination of AI and blockchain-enabled software with real-world pharmacy and clinical operations. Its vertical-integration model and developing precision-medicine efforts create a distinctive profile in the healthcare technology arena. For investors, MEDS provides a window into the convergence of artificial intelligence, pharmacy services, and personalized care—trends that continue to influence the wider healthcare sector.
When analyzing names like this, I often turn to Tickeron’s AI Screener to quickly filter opportunities across technical indicators, fundamentals, volatility, trends, and industry patterns. The platform lets me screen thousands of stocks and ETFs efficiently and surface ideas that align with specific strategies. It has become a regular part of my workflow for spotting comparable names or validating themes in health IT.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MEDS moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend. In 25 of 27 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
The 10-day moving average for MEDS crossed bearishly below the 50-day moving average on October 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MEDS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for MEDS entered a downward trend on November 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +4.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where MEDS advanced for three days, in 138 of 172 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
MEDS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (14.423). P/E Ratio (0.000) is within average values for comparable stocks, (11.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.016). Dividend Yield (0.000) settles around the average of (0.134) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (4.260).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. MEDS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MEDS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalDistributors